, Volume 22, Issue 2, pp 170–178 | Cite as

Increased androgen secretion in patients with prolactinomas: the impact of altered HPA function

  • Yosra Moria
  • Rouba Kortbawi
  • Nadine EL-Asmar
  • Baha M. ArafahEmail author


Background and objectives

Earlier studies suggested that hyperprolactinemia was associated with elevated serum DHEA-S levels. The importance of DHEA-S measurements in the diagnosis of adrenal insufficiency prompted us to assess adrenal androgen levels in hyperprolactinemic subjects with normal or impaired function.


Prospective study including 122 medically treated and 26 surgically patients with prolactinomas. Serum PRL, DHEA and DHEA-S levels were measured before and repeatedly after cabergoline therapy and also in the perioperative period of surgically treated patients.


Serum PRL levels decreased (P < 0.001) in all 101 medically treated patients with normal HPA function from 728.3 ± 1507 reaching 29.1 ± 39 and 14.9 ± 24.4 µg/L at 3 and 12 months, respectively. Concurrently serum DHEA-S levels decreased (P < 0.001) from 245.9 ± 196 to 216.2 ± 203.3 and to 169.7 ± 121.1 µg/dl at 3 and 12 months, respectively. These effects were reversed in 19 patients who discontinued treatment and were re-demonstrated after therapy resumption. Among the 22 surgically treated patients with normal HPA, peri-operative PRL levels decreased rapidly (P < 0.001) with a parallel decline in serum DHEA-S levels (P = 0.03). Strong correlations were noted between PRL and DHEA-S decrements observed with medical or surgical therapy. Medically (n = 21) and surgically (n = 4) patients with impaired HPA function had very low DHEA-S values that were unchanged despite marked reductions in PRL secretion.


Hyperprolactinemia is associated with a reproducible and reversible increase in serum DHEA-S that was observed in medically- and surgically-treated patients with normal HPA function. Thus, a normal age- and gender-adjusted serum DHEA-S level continues to imply normal HPA function even among hyperprolactinemic subjects.


Prolactinoma DHEA-S Hypothalamic–pituitary–adrenal axis 



This work was funded by local/departmental grant.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Nasrallah MP, Arafah BM (2003) The value of dehydroepiandrosterone sulfate measurements in the assessment of adrenal function. J Clin Endocrinol Metab 88:5293–5298CrossRefGoogle Scholar
  2. 2.
    Fischli S, Jenni S, Allemann S, Zwahlen M, Diem P, Christ ER, Stettler C et al (2008) Dehydroepiandrosterone sulfate in the assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 93:539–542CrossRefGoogle Scholar
  3. 3.
    Al-Aridi R, Abdelmannan D, Arafah BM (2011) Biochemical diagnosis of adrenal insufficiency: the added value of DHEA-S measurements. Endocrine Pract 17:261–270CrossRefGoogle Scholar
  4. 4.
    Sayyed Kassem L, El Sibai K, Chaiban J, Abdelmannan D, Arafah BM (2012) Measurements of serum DHEA and DHEA-S levels improve the accuracy of low dose cosyntropin test in the diagnosis of central adrenal insufficiency. J Clin Endocrinol Metab 97:3655–3663CrossRefGoogle Scholar
  5. 5.
    Khawandanah D, ElAsmar N, Arafah BM (2019) Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing’s syndrome and others with incidentalomas and subclinical hypercortisolism. Endocrine 63:140–148CrossRefGoogle Scholar
  6. 6.
    Dennedy MC, Annmalai AK, Prankerd-Smith O, Freeman N, Vengopal K, Graggaber J, Koulouri O, Powlson AS, Shaw A, Halsall DJ, Gunnell M (2017) Low DHEA-S: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. J Clin Endocrinol Metab 102:786–792Google Scholar
  7. 7.
    Vermeullin A, Ando S (1978) Prolactin and adrenal androgen secretion. Clin Endocrinol 8:295–303CrossRefGoogle Scholar
  8. 8.
    Bassi F, Giusti G, Borsi L, Attaneo S, Giannoti P, Forti G, Pazzagli M, Vigiani C, Serio M (1977) Plasma androgens in women with hyperprolactinemic amenorrhea. Clin Endocrinol 6:5–10CrossRefGoogle Scholar
  9. 9.
    Kandeel FR, Rudd BT, Butt WR, Edwards RL, London DR (1978) Androgen and cortisol responses to ACTH stimulation in women with hyperprolactinemia. Clin Endocrinol 9:123–130CrossRefGoogle Scholar
  10. 10.
    Lobo RA, Kletzky OA (1982) Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia. J Clin Endocrinol Metab 56:562–566CrossRefGoogle Scholar
  11. 11.
    Schiebinger RJ, Chrousos GP, Cutler GB Jr, Loriaux DL (1986) The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 62:202–209CrossRefGoogle Scholar
  12. 12.
    Serafini P, Lobo RA (1986) Prolactin modulates peripheral androgen metabolism. Fertil Steril 45:41–46CrossRefGoogle Scholar
  13. 13.
    Parker LN, Chang S, Odell WD (1878) Adrenal androgens in women with hyperprolactinemic amenorrhea. Clin Endocrinol 8:1–5CrossRefGoogle Scholar
  14. 14.
    Metcalf MG, Espiner EA, Donald RA (1979) Lack of effect of prolactin suppression on plasma dehydroepiandrosterone sulphate. Clin Endocrinol 10:539–544CrossRefGoogle Scholar
  15. 15.
    Belisle S, Menard J (1980) Adrenal androgen production in hyperprolactinemic states. Fertil Steril 33:396–400CrossRefGoogle Scholar
  16. 16.
    Arafah BM, Kailani SH, Nekl KE, Gold RS, Selman WR (1994) Immediate recovery of pituitary function following transsphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab 79:348–354Google Scholar
  17. 17.
    El-Asmar N, El-Sibai K, Al-Aridi R, Selman WR, Arafah BM (2016) Post operatively sellar hematoma after pituitary surgery: clinical and biochemical characteristics. Eur J Endocrinol 174:573–582CrossRefGoogle Scholar
  18. 18.
    Cheres AF, ElAsmar N, Rajpal A, Selman WR, Arafah BM (2017) Peri-operative hypothalamic-pituitary-adrenal function in patients with silent corticotroph adenomas. Pituitary 20(4) 471–476. CrossRefGoogle Scholar
  19. 19.
    El-Sibai K, Rajpal A, Selman WR, Arafah BM (2017) The impact peri-operative dexamethasone administration on the normal hypothalamic pituitary adrenal response to major surgical procedures. Endocrine 58:134–142CrossRefGoogle Scholar
  20. 20.
    Arafah BM, Brodkey JS, Pearson OH (1986) Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism 35:905–912CrossRefGoogle Scholar
  21. 21.
    Counts DR, Pescovitz OH, Barnes KM, Hench KD, Chrousos GP, Sherins RJ, Comite F, Loriaux DL, Cutler GB Jr (1987) Dissociation of adrenarche and gonadarche in precocious puberty and in isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 64:1174–1178CrossRefGoogle Scholar
  22. 22.
    Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF (1999) DHEA and DHEA-S: a review. J Clin Pharmacol 39:327–348CrossRefGoogle Scholar
  23. 23.
    Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper J (2000) A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 85:2832–2838Google Scholar
  24. 24.
    Warfield A, Finkel DM, Schatz NJ, Savino PJ, Snyder PJ (1884) Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function Ann Intern Med 101:783–785CrossRefGoogle Scholar
  25. 25.
    Arafah BM (1986) Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 62:1173–1179CrossRefGoogle Scholar
  26. 26.
    Griffing GT, Allen J, Pratt H, Melby JC (1985) Discordance of plasma DHEA-S and cortisol responses with various ACTH regiments. Metabolism 7:631–636CrossRefGoogle Scholar
  27. 27.
    Parker LN (1991) Control of adrenal androgen secretion. Endocrinol Metab Clin N Am 20:401–421CrossRefGoogle Scholar
  28. 28.
    Posner BI, Kelly PA, Shiu RPC, Freisen HG (1974) Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation, and characterization. Endocrinology 95:521–531CrossRefGoogle Scholar
  29. 29.
    Higuchi K, Nawat H, Maki T, Higashizima M, Kato KI, Ibayashi H (1983) Prolactin has a direct effect on adrenal androgen secretion. J Clin Endocrinol Metab 59:714–718CrossRefGoogle Scholar
  30. 30.
    Yamaji T, Ishibashi M, Takaku F, Itabashi A, Katayama S, Ishii J (1987) Serum dehydroepiandrosterone sulfate concentrations in secondary adrenal insufficiency. J Clin Endocrinol Metab 65:448–451CrossRefGoogle Scholar
  31. 31.
    Charoensri S, Chailurkit L, Muntham D, Bunnag P (2017) Serum dehydroepiandrosterone sulfate in assessing the integrity of hypothalamic pituitary adrenal axis. J Clin Transl Endocrinol 7:42–46Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Yosra Moria
    • 1
  • Rouba Kortbawi
    • 1
  • Nadine EL-Asmar
    • 1
  • Baha M. Arafah
    • 1
    Email author
  1. 1.Division of Clinical and Molecular EndocrinologyUH Cleveland Medical Center and Case Western UniversityClevelandUSA

Personalised recommendations